These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26935296)

  • 1. Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations?
    Sarmiento JM; Mukherjee D; Black KL; Fan X; Hu JL; Nuno MA; Patil CG
    J Neurol Surg A Cent Eur Neurosurg; 2016 May; 77(3):195-200. PubMed ID: 26935296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystic glioblastoma: an evaluation of IDH1 status and prognosis.
    Sarmiento JM; Nuño M; Ortega A; Mukherjee D; Fan X; Black KL; Patil CG
    Neurosurgery; 2014 Jan; 74(1):71-5: discussion 75-6. PubMed ID: 24089051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
    Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
    Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
    de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
    Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
    Amelot A; De Cremoux P; Quillien V; Polivka M; Adle-Biassette H; Lehmann-Che J; Françoise L; Carpentier AF; George B; Mandonnet E; Froelich S
    PLoS One; 2015; 10(7):e0130596. PubMed ID: 26158269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
    Khan I; Waqas M; Shamim MS
    J Pak Med Assoc; 2017 May; 67(5):816-817. PubMed ID: 28507382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
    Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
    Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
    Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
    Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
    Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
    J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival after glioblastoma resection: hope despite poor prognosis factors.
    Costa E; Lawson TM; Lelotte J; Fomekong E; Vaz RG; Renard L; Whenham N; Raftopoulos C
    J Neurosurg Sci; 2019 Jun; 63(3):251-257. PubMed ID: 29363298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
    Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
    Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
    Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN
    Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
    Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
    Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
    Paldor I; Drummond KJ; Kaye AH
    J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.